Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease

Ozlem Goker-Alpan, Edythe A. Wiggs, Michael J. Eblan, William Benko, Shira G. Ziegler, Ellen Sidransky, Raphael Schiffmann

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: To investigate the spectrum and prevalence of cognitive deficits among children with type 3 (chronic neuronopathic) Gaucher disease (GD). Study design: A case review study identified 32 children (male/female; 17:15) with type 3 GD who had received enzyme replacement therapy (ERT) or a bone marrow transplant. The diagnosis of GD was established by enzymatic assay and DNA testing. Subjects were assessed with standard neuropsychological testing, and data from the most recent evaluation were included. Results: Neuropsychometric assessments demonstrated a wide spectrum of full-scale IQ scores ranging from 39 to 124 (mean 75). About 60% of subjects had intellectual skills below average. There were significant discrepancies between verbal and performance IQ, with a range between -6 and 38 points (P = .02). This gap was more prominent in older subjects, with better performance in the verbal areas. No correlation was observed between intelligence measures and genotype or the extent of systemic involvement. The dosage, age at initiation, and the length of ERT had no significant effect on IQ scores. Conclusions: In type 3 GD, cognitive deficits, characterized by visual-spatial dysfunction, are common but underappreciated and appear resistant to ERT.

Original languageEnglish (US)
JournalJournal of Pediatrics
Volume153
Issue number1
DOIs
StatePublished - Jul 1 2008
Externally publishedYes

Fingerprint

Gaucher Disease
Enzyme Replacement Therapy
Enzyme Assays
Intelligence
Bone Marrow
Genotype
Transplants
DNA

ASJC Scopus subject areas

  • Medicine(all)
  • Pediatrics, Perinatology, and Child Health

Cite this

Goker-Alpan, O., Wiggs, E. A., Eblan, M. J., Benko, W., Ziegler, S. G., Sidransky, E., & Schiffmann, R. (2008). Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease. Journal of Pediatrics, 153(1). https://doi.org/10.1016/j.jpeds.2007.12.023

Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease. / Goker-Alpan, Ozlem; Wiggs, Edythe A.; Eblan, Michael J.; Benko, William; Ziegler, Shira G.; Sidransky, Ellen; Schiffmann, Raphael.

In: Journal of Pediatrics, Vol. 153, No. 1, 01.07.2008.

Research output: Contribution to journalArticle

Goker-Alpan, O, Wiggs, EA, Eblan, MJ, Benko, W, Ziegler, SG, Sidransky, E & Schiffmann, R 2008, 'Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease', Journal of Pediatrics, vol. 153, no. 1. https://doi.org/10.1016/j.jpeds.2007.12.023
Goker-Alpan, Ozlem ; Wiggs, Edythe A. ; Eblan, Michael J. ; Benko, William ; Ziegler, Shira G. ; Sidransky, Ellen ; Schiffmann, Raphael. / Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease. In: Journal of Pediatrics. 2008 ; Vol. 153, No. 1.
@article{303802e63f94437a8aef515085aa66bd,
title = "Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease",
abstract = "Objective: To investigate the spectrum and prevalence of cognitive deficits among children with type 3 (chronic neuronopathic) Gaucher disease (GD). Study design: A case review study identified 32 children (male/female; 17:15) with type 3 GD who had received enzyme replacement therapy (ERT) or a bone marrow transplant. The diagnosis of GD was established by enzymatic assay and DNA testing. Subjects were assessed with standard neuropsychological testing, and data from the most recent evaluation were included. Results: Neuropsychometric assessments demonstrated a wide spectrum of full-scale IQ scores ranging from 39 to 124 (mean 75). About 60{\%} of subjects had intellectual skills below average. There were significant discrepancies between verbal and performance IQ, with a range between -6 and 38 points (P = .02). This gap was more prominent in older subjects, with better performance in the verbal areas. No correlation was observed between intelligence measures and genotype or the extent of systemic involvement. The dosage, age at initiation, and the length of ERT had no significant effect on IQ scores. Conclusions: In type 3 GD, cognitive deficits, characterized by visual-spatial dysfunction, are common but underappreciated and appear resistant to ERT.",
author = "Ozlem Goker-Alpan and Wiggs, {Edythe A.} and Eblan, {Michael J.} and William Benko and Ziegler, {Shira G.} and Ellen Sidransky and Raphael Schiffmann",
year = "2008",
month = "7",
day = "1",
doi = "10.1016/j.jpeds.2007.12.023",
language = "English (US)",
volume = "153",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease

AU - Goker-Alpan, Ozlem

AU - Wiggs, Edythe A.

AU - Eblan, Michael J.

AU - Benko, William

AU - Ziegler, Shira G.

AU - Sidransky, Ellen

AU - Schiffmann, Raphael

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Objective: To investigate the spectrum and prevalence of cognitive deficits among children with type 3 (chronic neuronopathic) Gaucher disease (GD). Study design: A case review study identified 32 children (male/female; 17:15) with type 3 GD who had received enzyme replacement therapy (ERT) or a bone marrow transplant. The diagnosis of GD was established by enzymatic assay and DNA testing. Subjects were assessed with standard neuropsychological testing, and data from the most recent evaluation were included. Results: Neuropsychometric assessments demonstrated a wide spectrum of full-scale IQ scores ranging from 39 to 124 (mean 75). About 60% of subjects had intellectual skills below average. There were significant discrepancies between verbal and performance IQ, with a range between -6 and 38 points (P = .02). This gap was more prominent in older subjects, with better performance in the verbal areas. No correlation was observed between intelligence measures and genotype or the extent of systemic involvement. The dosage, age at initiation, and the length of ERT had no significant effect on IQ scores. Conclusions: In type 3 GD, cognitive deficits, characterized by visual-spatial dysfunction, are common but underappreciated and appear resistant to ERT.

AB - Objective: To investigate the spectrum and prevalence of cognitive deficits among children with type 3 (chronic neuronopathic) Gaucher disease (GD). Study design: A case review study identified 32 children (male/female; 17:15) with type 3 GD who had received enzyme replacement therapy (ERT) or a bone marrow transplant. The diagnosis of GD was established by enzymatic assay and DNA testing. Subjects were assessed with standard neuropsychological testing, and data from the most recent evaluation were included. Results: Neuropsychometric assessments demonstrated a wide spectrum of full-scale IQ scores ranging from 39 to 124 (mean 75). About 60% of subjects had intellectual skills below average. There were significant discrepancies between verbal and performance IQ, with a range between -6 and 38 points (P = .02). This gap was more prominent in older subjects, with better performance in the verbal areas. No correlation was observed between intelligence measures and genotype or the extent of systemic involvement. The dosage, age at initiation, and the length of ERT had no significant effect on IQ scores. Conclusions: In type 3 GD, cognitive deficits, characterized by visual-spatial dysfunction, are common but underappreciated and appear resistant to ERT.

UR - http://www.scopus.com/inward/record.url?scp=47649097065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649097065&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2007.12.023

DO - 10.1016/j.jpeds.2007.12.023

M3 - Article

C2 - 18571543

AN - SCOPUS:47649097065

VL - 153

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -